Webinar | October 20, 2017

Reducing Mab Clinical Trial Costs By Using Different Agarose Protein A Chromatography Resins

Source: Purolite Life Sciences

Presenting a case study that reduces MAb clinical trial development costs by up to 65% using different agarose Protein A chromatography resins. New data from a HTPD comparability case study is shared using three Protein A resins, with key data including yield, purity, DNA & HCP clearance, and Protein A leakage. Purolite Life Sciences' Applications Manager Hans Johansson presents, utilizing over 30 years in the Biotech business to help you transform your processes today.